Summary & Overview
HCPCS J7528: Mycophenolate Mofetil Oral Suspension, 100 mg
HCPCS Level II code J7528 denotes mycophenolate mofetil, for suspension, oral, 100 mg, a commonly used oral immunosuppressant in transplant medicine and certain autoimmune conditions. Nationally, accurate coding for oral formulations matters for pharmacy billing, formularies, and coverage determinations because it affects patient access to maintenance therapies and plan cost-management. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of the code's clinical context and typical service settings, plus what to expect when this code appears on claims. The publication summarizes payer coverage considerations and common charge/ reimbursement benchmarking themes where available, highlights policy updates that affect pharmacy billing and prior authorization practices, and outlines operational notes for outpatient and pharmacy-dispensed oral medications. This material is intended for billing managers, pharmacists, revenue cycle staff, and policy analysts who need a national perspective on how J7528 is used in claims and coverage workflows. Data not available in the input is clearly noted where applicable.
Billing Code Overview
HCPCS Level II code J7528 represents mycophenolate mofetil, for suspension, oral, 100 mg. This code describes the medication formulation and unit of measure for billing purposes.
Service type: oral anti-rejection/immunosuppressive medication administration (dispensed for patient use)
Typical site of service: outpatient pharmacies, outpatient clinic dispensing, and home administration after pharmacy dispensing
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with an autoimmune condition such as systemic lupus erythematosus, rheumatoid arthritis, or as maintenance therapy after organ transplantation who requires long-term oral immunosuppression. A clinician prescribes J7528 (mycophenolate mofetil, for suspension, oral, 100 mg) when an oral liquid formulation is indicated because of swallowing difficulty, need for dose titration in pediatrics, or precise dosing for patients with altered pharmacokinetics. The clinical workflow begins with a clinician evaluation documenting diagnosis, indication, and dose. A prescription for the suspension is sent to a specialty pharmacy or compounding pharmacy; prior authorization may be obtained from the patient’s payor (for example, Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, Medicare) if required. The patient receives counseling on administration, dosing frequency, adverse effects (e.g., infection risk, gastrointestinal upset), and monitoring requirements. Follow-up visits include laboratory monitoring (complete blood count, liver function tests, renal function) and assessments for therapeutic effect and adverse events. Medication reconciliation and documentation of the medication formulation (J7528) are included in the medical record and in discharge or clinic summaries when applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When additional work or time is required for medication management or complex counseling beyond usual practice related to J7528 administration |
24 | Unrelated evaluation and management service by the same physician during a postoperative period | When an unrelated E/M occurs on the same day as ordering or managing J7528 during a global period |
25 | Significant, separately identifiable E/M service by the same physician on the same day of a procedure | When a significant E/M is performed the same day as initiating therapy with J7528 and must be reported separately |
26 | Professional component | When delineating physician professional service for services that have a split professional/technical component related to medication preparation or consultation |
52 | Reduced services | When a planned service related to medication management is partially reduced or not fully performed |
59 | Distinct procedural service | When a separate, distinct service (e.g., a separate medication administration or counseling encounter) is performed on the same day as another service |
76 | Repeat procedure by same physician | When a medication-related procedure or administration is repeated by the same provider on the same day |
77 | Repeat procedure by another physician | When repeated by a different provider on the same day |
91 | Repeat clinical diagnostic laboratory test | When laboratory monitoring related to J7528 therapy (e.g., CBC) is repeated within the same encounter timeframe |
JW | Drug amount discarded/not administered to any patient | When part of a dispensed dose is discarded and documentation is required for wastage reporting |
KX | Requirements specified in the medical policy have been met | When prior authorization criteria for coverage of J7528 are met per payor policy |
AH | Hospital outpatient: Hospital provided services | When the medication is provided in the hospital outpatient setting and facility billing distinctions apply |
QB | Drug administered at home | When medication is provided and administered in the home setting under applicable billing scenarios |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207RC0000X | Rheumatology | Manages autoimmune diseases commonly treated with mycophenolate mofetil |
207LN0001X | Nephrology | Manages transplant immunosuppression and glomerular diseases requiring mycophenolate |
207RH0000X | Allergy & Immunology | Manages autoimmune and immunologic disorders requiring steroid-sparing agents |
2080P0207X | Transplant Surgery | Manages post-transplant immunosuppressive regimens and medication selection |
163WP0800X | Clinical Pharmacist | Performs medication counseling, dose adjustments, and compounding oversight for suspension formulations |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
M32.10 | Systemic lupus erythematosus, organ or system involvement unspecified | Mycophenolate is commonly used for lupus nephritis and other manifestations requiring immunosuppression |
M05.9 | Rheumatoid arthritis with rheumatoid factor, unspecified | Mycophenolate may be used as a steroid-sparing agent in refractory rheumatoid disease |
N18.9 | Chronic kidney disease, unspecified | Used in management of glomerular diseases and transplant recipients where oral suspension may be needed |
T86.10 | Unspecified complication of kidney transplant | Mycophenolate is a mainstay of transplant immunosuppressive regimens to prevent rejection |
L93.0 | Discoid lupus erythematosus [DLE] | Mycophenolate is used off-label for cutaneous lupus when topical therapy is insufficient |
K50.90 | Crohn's disease, unspecified, without complications | Mycophenolate is sometimes used as an immunosuppressant in severe inflammatory bowel disease when other agents are unsuitable |
K52.9 | Noninfective gastroenteritis and colitis, unspecified | Relevant when oral suspension is chosen for patients with swallowing issues or GI absorption concerns |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | May be billed when parenteral immunosuppressive injections are administered in the same visit as initiation or monitoring of oral J7528 therapy |
99406 | Smoking and tobacco use cessation counseling, intermediate, greater than 3 minutes up to 10 minutes | Example of an E/M adjunct service that could be delivered during counseling visits when documenting significant counseling alongside J7528 management |
99407 | Smoking and tobacco use cessation counseling, intensive, greater than 10 minutes | For extended behavioral counseling provided in the same care episode where medication management for J7528 is addressed |
99490 | Chronic care management services, at least 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month | Related to ongoing management and monitoring for patients on chronic immunosuppressive therapy such as J7528 |
99213 | Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes | Common E/M code for routine follow-up visits to assess response and monitoring for patients prescribed J7528 |
36415 | Collection of venous blood by venipuncture | Frequently performed for laboratory monitoring (CBC, chemistry) required for safe use of J7528 |